Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
复制标题
DOI：
10.1038/sj.bjc.6603813
复制
发表时间：
2007-06-18
影响因子：
8.8
通讯作者：
McDonald, D M
中科院分区：
文献类型：
--
作者：
Kamba, T;McDonald, D M
了解血管内皮生长因子（VEGF）在正常生理学中的作用的进展，使人们深入了解在临床肿瘤学中使用VEGF抑制剂引起的不良反应的基础。这些效应通常是在微血管系统的调节和维持中重要的细胞信号传导途径抑制的下游后果。这些途径在正常器官中的下调可导致血管紊乱，甚至血管退化，其可通过并发的病理条件而加剧。这些变化通常是可管理的，并且比正在治疗的肿瘤造成的风险更小，但它们突出了肿瘤血管和正常器官血管系统所共有的特性。
Advances in understanding the role of vascular endothelial growth factor (VEGF) in normal physiology are giving insight into the basis of adverse effects attributed to the use of VEGF inhibitors in clinical oncology. These effects are typically downstream consequences of suppression of cellular signalling pathways important in the regulation and maintenance of the microvasculature. Downregulation of these pathways in normal organs can lead to vascular disturbances and even regression of blood vessels, which could be intensified by concurrent pathological conditions. These changes are generally manageable and pose less risk than the tumours being treated, but they highlight the properties shared by tumour vessels and the vasculature of normal organs.